Last updated: July 8, 2026
Norethindrone and ethinyl estradiol and ferrous fumarate is a fixed-dose combined oral contraceptive (COC) using a standard daily-pill cyclic regimen plus an iron supplement. Investment fundamentals hinge on (1) how the product is positioned in the market versus generic COCs and generic “low-dose iron” add-ons, (2) whether exclusivity or patent barriers materially delay generic entry, and (3) whether the product’s FDA listing and patent estate meaningfully deter Paragraph IV (PIV) challenges.
No revenue, patent list, Orange Book status, or litigation docket details are provided here, so an investment-grade assessment cannot be completed to the standard required for high-stakes R&D, licensing, litigation, or investment decisions.
What patents protect norethindrone and ethinyl estradiol and ferrous fumarate combination products?
Featured-snippet answer: Patent protection, if any, typically clusters around listed Orange Book patents for the drug product, formulation/composition, and specific dosing regimens using the iron component.
Without the specific FDA application reference (NDA/ANDA number), strength(s), and brand name tied to the ferrous fumarate add-on, the patent estate cannot be mapped to specific claims, expiration dates, or enforceability status.
Drug product vs. “iron add-on” IP: where claims usually sit
Typical US patent clusters for COC-with-iron combinations include:
- Drug product patents covering the finished dosage form and film-coating or tablet structure.
- Formulation/composition patents addressing excipients and stability.
- Method-of-use patents sometimes tied to a regimen that uses the iron portion to reduce pill fatigue and maintain adherence.
However, identifying which exact patents cover this product requires the Orange Book-listed patents for the specific NDA.
Which assignees and expiration dates matter to investors?
Investors need:
- Patent numbers (US publication and grant)
- Assignees/owners
- Expiration (including terminal disclaimers)
- Patent term adjustments and pediatric exclusivity, if applicable
- Whether patents are Orange Book “listed” (i.e., tied to an approved NDA)
No such dataset is included in the request.
When does norethindrone/ethinyl estradiol/ferrous fumarate lose exclusivity?
Featured-snippet answer: Exclusivity loss is driven by the NDA’s marketing exclusivity (if any) and by the specific Orange Book patents’ scheduled expiration, plus any regulatory exclusivity extensions.
A correct exclusivity timeline requires:
- The NDA approval year and 5-year/3-year exclusivity triggers (new chemical entity, new clinical investigation, etc.)
- Any pediatric exclusivity
- The Orange Book listed patents and their projected expiration dates
Those inputs are not provided.
What is the Orange Book status of NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?
Featured-snippet answer: Orange Book status is determined per FDA application and lists associated patents and whether they are drug substance, drug product, or method-of-use.
A complete Orange Book mapping must be done from the specific NDA/ANDA identifier. The request does not specify an NDA/brand or strength/formulation details (which products often exist under the same broad ingredient set with different regimens and iron strengths).
How strong is the patent estate for norethindrone/ethinyl estradiol plus iron tablets?
Featured-snippet answer: Strength depends on claim scope (formulation, composition, regimen), remaining life, and whether any patents are eligible to block generic approval for the same listed indications/dosages.
To quantify strength, an investor needs:
- Counts of Orange Book patents by category (composition, formulation, method)
- Claims relevant to generic design-around
- Remaining term in years and months
- Litigation or CMC constraints that increase settlement likelihood
No patent list or term data is provided, so the patent strength cannot be scored.
What generic entry risks exist for this combined oral contraceptive with ferrous fumarate?
Featured-snippet answer: Generic entry risk is highest when the product has (a) limited remaining patent life, (b) patents that are easier to design around, and (c) heavy market precedent for generic COCs with similar iron components.
A risk model requires:
- Whether generics already exist for the same exact regimen
- Whether PIV filings have occurred for the same NDA
- Whether 505(b)(2) or ANDA pathways are in play and how label carveouts affect design
None of those status indicators can be evaluated without the relevant FDA application mapping.
What patent litigation affects norethindrone and ethinyl estradiol and ferrous fumarate products?
Featured-snippet answer: Litigation risk exists if ANDA filers challenge Orange Book patents through PIV notices and the NDA sponsor litigates or settles via consent decrees.
An accurate litigation impact analysis requires:
- Court dockets (e.g., District Court for Delaware, New Jersey, Massachusetts, etc.)
- Case numbers
- Asserted patents
- Settlement terms (runway, injunction scope, design-around provisions)
- Triggered launch dates
No litigation information is included.
How many patents cover norethindrone/ethinyl estradiol/ferrous fumarate by formulation, method of use, and drug product?
Featured-snippet answer: The number of patents is defined by the Orange Book listing for the exact FDA product application.
A numerically correct patent count cannot be produced without the Orange Book patent listing.
Which companies sell and challenge this iron-containing COC in the US market?
Featured-snippet answer: The competitive set includes branded incumbents (if any), multiple generic COC suppliers, and any ANDA filers who have matched the same regimen and iron component timing.
To identify companies and assess competitive pressure, the analysis needs:
- Brand name
- Strengths and regimen (number of active days and number of iron days)
- Market share and wholesaler inventory behavior
- FDA approvals and Paragraph IV challengers
No product identifier is provided.
What regulatory pathway and FDA status applies to this COC with ferrous fumarate?
Featured-snippet answer: Most generic versions use the ANDA pathway, leveraging bioequivalence for active hormones and matching dosage form and iron schedule requirements.
A complete regulatory risk view requires:
- FDA application type for the listed product
- Reference listed drug (RLD) status
- Bioequivalence basis and labeling match requirements
- Any risk of clinical superiority or formulation-specific stability issues
No regulatory application data is provided.
What formulations are protected by patents for norethindrone/ethinyl estradiol/ferrous fumarate?
Featured-snippet answer: Formulation protection typically targets excipient systems, tablet core/coating architecture, and stability around hormone integrity while co-administering iron.
To identify protected formulations, the specific Orange Book formulation/composition patents and their claim language must be listed. That dataset is not provided.
How does this drug compare with other iron-containing oral contraceptives in terms of market and IP barriers?
Featured-snippet answer: Investment differentiation comes from whether the competitor has an IP moat (later expiration, broader claims) or from whether the regimen is identical such that generic entry is straightforward.
A proper comparison requires two products’ Orange Book and patent estates side-by-side, plus their FDA labeling differences. No comparator list or product identifiers are provided.
What is the expected generic launch scenario for this product under current exclusivity and patent status?
Featured-snippet answer: Generic launch depends on patent expiration and settlement timing. If patents are unexpired and not settled, launch timing is usually delayed by injunctions or lack of final approval.
Without Orange Book expiration dates and any settlement history, launch timing cannot be modeled.
Commercial fundamentals: what drives demand and pricing for an iron-containing COC?
Featured-snippet answer: Demand is shaped by contraceptive adherence and tolerability, with the iron component addressing adherence through routine and potentially anemia-related value messaging. Pricing pressure is driven by generic penetration of the active hormones and by reimbursement dynamics.
An investor-grade commercial model needs:
- Net sales trend and payer mix
- Rebate and list price vs net price
- Inventory cycles and wholesaler buying
- Share of stomach-tolerability and withdrawal/discontinuation impacts
None of this commercial KPI data is provided.
Key Takeaways
- A defensible investment and risk analysis for norethindrone and ethinyl estradiol and ferrous fumarate requires the specific FDA application (NDA/brand) to map Orange Book exclusivity, patents, expiration dates, and litigation.
- Without the product identifier and Orange Book/patent dataset, patent-barrier strength, generic entry timing, and settlement/injunction scenarios cannot be quantified.
- Commercial fundamentals cannot be valued without market share, pricing, and reimbursement inputs tied to the exact product strength and regimen.
FAQs
- How do Orange Book patent categories (drug substance vs drug product vs method of use) typically affect ANDA approval for COCs?
- What signs in FDA labeling indicate whether an iron component creates regimen-specific patent exposure?
- How do Paragraph IV settlements usually translate into launch “at-risk” dates for older combination products?
- What formulation attributes can delay generic substitution for hormone and iron tablets?
- How should investors benchmark an iron-containing COC’s generic risk versus standard low-dose COCs without iron?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
- FDA. Application Integrity Policy and 505(b)(2)/ANDA approval pathway guidance. (FDA guidance documents and regulatory materials).
